Oragenics Inc (OGEN)
Oragenics, Inc. is a development-stage biotechnology company focused on researching and developing nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases in the United States. Its lead candidate is ONP-002, a fully synthetic neurosteroid designed to cross the blood-brain barrier and target swelling, oxidative stress, and inflammation in the treatment of mild traumatic brain injury. The company, formerly known as Oragen, Inc., was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida. Oragenics common stock trades on the New York Stock Exchange under the symbol OGEN.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-OGEN
|
$0.86
|
59.7% Upside
|
Bargain
|
$2
|
270.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-0.2x
|
0.4x
|
—
|
2.441 M
|
-3.613 M
|
2.2%
|
98.1%
|
-94.6
|
—
|
95.0%
|
